363 related articles for article (PubMed ID: 25820276)
1. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy.
Bol GM; Vesuna F; Xie M; Zeng J; Aziz K; Gandhi N; Levine A; Irving A; Korz D; Tantravedi S; Heerma van Voss MR; Gabrielson K; Bordt EA; Polster BM; Cope L; van der Groep P; Kondaskar A; Rudek MA; Hosmane RS; van der Wall E; van Diest PJ; Tran PT; Raman V
EMBO Mol Med; 2015 May; 7(5):648-69. PubMed ID: 25820276
[TBL] [Abstract][Full Text] [Related]
2. RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3.
Xie M; Vesuna F; Tantravedi S; Bol GM; Heerma van Voss MR; Nugent K; Malek R; Gabrielson K; van Diest PJ; Tran PT; Raman V
Cancer Res; 2016 Nov; 76(21):6340-6350. PubMed ID: 27634756
[TBL] [Abstract][Full Text] [Related]
3. Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.
Heerma van Voss MR; Vesuna F; Trumpi K; Brilliant J; Berlinicke C; de Leng W; Kranenburg O; Offerhaus GJ; Bürger H; van der Wall E; van Diest PJ; Raman V
Oncotarget; 2015 Sep; 6(29):28312-26. PubMed ID: 26311743
[TBL] [Abstract][Full Text] [Related]
4. Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment.
Heerma van Voss MR; Vesuna F; Bol GM; Afzal J; Tantravedi S; Bergman Y; Kammers K; Lehar M; Malek R; Ballew M; Ter Hoeve N; Abou D; Thorek D; Berlinicke C; Yazdankhah M; Sinha D; Le A; Abrahams R; Tran PT; van Diest PJ; Raman V
Oncogene; 2018 Jan; 37(1):63-74. PubMed ID: 28869602
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V
Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868
[TBL] [Abstract][Full Text] [Related]
6. RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma.
Wilky BA; Kim C; McCarty G; Montgomery EA; Kammers K; DeVine LR; Cole RN; Raman V; Loeb DM
Oncogene; 2016 May; 35(20):2574-83. PubMed ID: 26364611
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of DEAD-Box RNA Helicase 3 attenuates stress granule assembly.
Cui BC; Sikirzhytski V; Aksenova M; Lucius MD; Levon GH; Mack ZT; Pollack C; Odhiambo D; Broude E; Lizarraga SB; Wyatt MD; Shtutman M
Biochem Pharmacol; 2020 Dec; 182():114280. PubMed ID: 33049245
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the Dead Box RNA Helicase 3 Prevents HIV-1 Tat and Cocaine-Induced Neurotoxicity by Targeting Microglia Activation.
Aksenova M; Sybrandt J; Cui B; Sikirzhytski V; Ji H; Odhiambo D; Lucius MD; Turner JR; Broude E; Peña E; Lizarraga S; Zhu J; Safro I; Wyatt MD; Shtutman M
J Neuroimmune Pharmacol; 2020 Jun; 15(2):209-223. PubMed ID: 31802418
[TBL] [Abstract][Full Text] [Related]
9. NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3.
Xie M; Vesuna F; Botlagunta M; Bol GM; Irving A; Bergman Y; Hosmane RS; Kato Y; Winnard PT; Raman V
Oncotarget; 2015 Oct; 6(30):29901-13. PubMed ID: 26337079
[TBL] [Abstract][Full Text] [Related]
10. Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33.
Tantravedi S; Vesuna F; Winnard PT; Martin A; Lim M; Eberhart CG; Berlinicke C; Raabe E; van Diest PJ; Raman V
Transl Oncol; 2019 Jan; 12(1):96-105. PubMed ID: 30292066
[TBL] [Abstract][Full Text] [Related]
11. PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3.
Bol GM; Khan R; Heerma van Voss MR; Tantravedi S; Korz D; Kato Y; Raman V
Cancer Chemother Pharmacol; 2015 Oct; 76(4):821-7. PubMed ID: 26330329
[TBL] [Abstract][Full Text] [Related]
12. RK-33 Is a Broad-Spectrum Antiviral Agent That Targets DEAD-Box RNA Helicase DDX3X.
Yang SNY; Atkinson SC; Audsley MD; Heaton SM; Jans DA; Borg NA
Cells; 2020 Jan; 9(1):. PubMed ID: 31936642
[TBL] [Abstract][Full Text] [Related]
13. Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir.
Rao S; Lungu C; Crespo R; Steijaert TH; Gorska A; Palstra RJ; Prins HAB; van Ijcken W; Mueller YM; van Kampen JJA; Verbon A; Katsikis PD; Boucher CAB; Rokx C; Gruters RA; Mahmoudi T
Nat Commun; 2021 Apr; 12(1):2475. PubMed ID: 33931637
[TBL] [Abstract][Full Text] [Related]
14. DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs.
Kukhanova MK; Karpenko IL; Ivanov AV
Molecules; 2020 Feb; 25(4):. PubMed ID: 32102413
[TBL] [Abstract][Full Text] [Related]
15. RNA Polymerase II-Associated Factor 1 Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions With PHF5A and DDX3.
Karmakar S; Rauth S; Nallasamy P; Perumal N; Nimmakayala RK; Leon F; Gupta R; Barkeer S; Venkata RC; Raman V; Rachagani S; Ponnusamy MP; Batra SK
Gastroenterology; 2020 Nov; 159(5):1898-1915.e6. PubMed ID: 32781084
[TBL] [Abstract][Full Text] [Related]
16. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.
Samal SK; Routray S; Veeramachaneni GK; Dash R; Botlagunta M
Sci Rep; 2015 Apr; 5():9982. PubMed ID: 25918862
[TBL] [Abstract][Full Text] [Related]
17. DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway.
Chen HH; Yu HI; Cho WC; Tarn WY
Oncogene; 2015 May; 34(21):2790-800. PubMed ID: 25043297
[TBL] [Abstract][Full Text] [Related]
18. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.
Raghavan P; Tumati V; Yu L; Chan N; Tomimatsu N; Burma S; Bristow RG; Saha D
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e507-14. PubMed ID: 22795803
[TBL] [Abstract][Full Text] [Related]
19. DDX3 acts as a tumor suppressor in colorectal cancer as loss of DDX3 in advanced cancer promotes tumor progression by activating the MAPK pathway.
Shen L; Zhang J; Xu M; Zheng Y; Wang M; Yang S; Qin B; Li S; Dong L; Dai F
Int J Biol Sci; 2022; 18(10):3918-3933. PubMed ID: 35844798
[No Abstract] [Full Text] [Related]
20. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
